Neal Edward Ready | Scholars@Duke

Neal Edward Ready
Professor of Medicine

Current Appointments & Affiliations

Professor of Medicine, Medicine, Medical Oncology, Medicine 2016
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2006

Contact Information

25178 Morris Bldg-200 Trent Dr., Box 3198, Durham, NC 27710
Duke Box 3198, Rm25178 Morris Bldg/ 200 Trent Dr., Durham, NC 27710
neal.ready@duke.edu (919) 681-6932

Background
Education, Training, & Certifications
- Fellow in Hematology-Oncology, Medicine, Tufts University 1992 - 1994
- Fellow in Hematology-Oncology, Medicine, Brown University 1990 - 1992
- Medical Resident, Medicine, Brown University 1986 - 1989
- M.D., Vanderbilt University 1986
- Ph.D., University of California at Irvine 1983
Duke Appointment History
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2014 - 2016
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2010 - 2014
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2006 - 2010
- Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2006
Research
Selected Grants
- ADRIATIC 2019 - 2024
- B9991023 2018 - 2023
- M16-300 2017 - 2022
- M16-298 (MERU) 2017 - 2022
- BMS CA209817 2017 - 2021
- TOP 1501 2016 - 2021
- BMS451 2016 - 2021
- TRINITY 2016 - 2021
- CheckMate 568 2016 - 2021
- An open-label, randomized, phase 3 trial of Nivolumab vs Investigator's choice chemotherapy as first-line therapy ofr st 2014 - 2020
- Condor 2015 - 2020
- A phase 1 / 2 multicenter study of BMS-986012 in subjects with relapsed/refractory small cell lung cnacer 2014 - 2020
- BMS CA 209-331-001 An Open label, Randomized Phase 3 Study of Nivolumab or Chemo 2015 - 2020
- A phase II, multi-center, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) 2015 - 2020
- An open label, randomized phase 3 clincal trial of Nivolumab vs therapy of investigator's choice in recurrent or metasti 2014 - 2020
- TESARO LUNG AND ENDOMETRIAL CANCER PRACTICUM 2019
- BMS PROTOTYPE LUNG PROGRAM - 3 DAY PROGRAMMING 2018 - 2019
- A phase II, multicenter, single-arm study of MPDL3280A in patients with advanced PD-L1_positive Locally advanced or Meta 2013 - 2018
- Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer 2015 - 2018
- A Phase I study to evaluate the saftey, phamocokinetics and pharmacodynamics of JNJ-42756493 a pan-fibroblat growth fact 2014 - 2018
- AFT_31_ALLIANCE FOUNDATION TRIAL 2017 - 2018
- BMS-227 2015 - 2018
- Phase I/II open label dose escalation study of the safety, pharmacokinetics, and preliminary efficacy of SCI6D6.5 as a s 2013 - 2018
- Abbvie M14-361 2015 - 2017
- Programs in Clinical Effectiveness of Cancer Pharmacogenomics awarded by National Institutes of Health 2009 - 2012
- Refining and Validating Genomic Signatures in Lung Cancer awarded by National Institutes of Health 2009 - 2010
External Relationships
- AbbVie
- Adnexis (Bristol-Myers Squibb)
- AstraZeneca
- Celgene Corporation
- G1 Therapeutics
- Genentech, Inc (Roche Holding)
- Merck & Co. USA (not assoc'd with Merck KGaA)
- Pfizer Inc.
- kura oncology
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Rhodin, Kristen E., A Justin Rucker, Neal E. Ready, Thomas A. D’Amico, and Scott J. Antonia. “The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.” J Thorac Cardiovasc Surg 159, no. 4 (April 2020): 1616–23. https://doi.org/10.1016/j.jtcvs.2019.08.138.
    Full Text Link to Item
  - Ready, Neal E., Patrick A. Ott, Matthew D. Hellmann, Jon Zugazagoitia, Christine L. Hann, Filippo de Braud, Scott J. Antonia, et al. “Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.” J Thorac Oncol 15, no. 3 (March 2020): 426–35. https://doi.org/10.1016/j.jtho.2019.10.004.
    Full Text Link to Item
  - Jacobs, Corbin D., Junheng Gao, Xiaofei Wang, Jeffrey M. Clarke, Betty Tong, Neal E. Ready, Gita Suneja, Chris R. Kelsey, and Jordan A. Torok. “Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.” Clin Lung Cancer, October 19, 2019. https://doi.org/10.1016/j.cllc.2019.10.005.
    Full Text Link to Item
  - Ready, Neal, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, et al. “First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.” J Clin Oncol 37, no. 12 (April 20, 2019): 992–1000. https://doi.org/10.1200/JCO.18.01042.
    Full Text Link to Item
  - Khoury, Tawfiq, David Jang, Ricardo Carrau, Neal Ready, Ian Barak, and Ralph Abi Hachem. “Role of induction chemotherapy in sinonasal malignancies: a systematic review.” Int Forum Allergy Rhinol 9, no. 2 (February 2019): 212–19. https://doi.org/10.1002/alr.22229.
    Full Text Link to Item
  - Ready, Neal, Anna F. Farago, Filippo de Braud, Akin Atmaca, Matthew D. Hellmann, Jeffrey G. Schneider, David R. Spigel, et al. “Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.” J Thorac Oncol 14, no. 2 (February 2019): 237–44. https://doi.org/10.1016/j.jtho.2018.10.003.
    Full Text Link to Item
  - Siu, Lillian L., Caroline Even, Ricard Mesía, Eva Remenar, Amaury Daste, Jean-Pierre Delord, Jürgen Krauss, et al. “Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.” Jama Oncol 5, no. 2 (February 1, 2019): 195–203. https://doi.org/10.1001/jamaoncol.2018.4628.
    Full Text Link to Item
  - Zandberg, Dan P., Alain P. Algazi, Antonio Jimeno, James S. Good, Jérôme Fayette, Nathaniel Bouganim, Neal E. Ready, et al. “Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.” Eur J Cancer 107 (January 2019): 142–52. https://doi.org/10.1016/j.ejca.2018.11.015.
    Full Text Link to Item
  - Liu, Stephen V., D Ross Camidge, Scott N. Gettinger, Giuseppe Giaccone, Rebecca S. Heist, F Stephen Hodi, Neal E. Ready, et al. “Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.” Eur J Cancer 101 (September 2018): 114–22. https://doi.org/10.1016/j.ejca.2018.06.033.
    Full Text Link to Item
  - Vokes, E. E., N. Ready, E. Felip, L. Horn, M. A. Burgio, S. J. Antonia, O. Arén Frontera, et al. “Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.” Ann Oncol 29, no. 4 (April 1, 2018): 959–65. https://doi.org/10.1093/annonc/mdy041.
    Full Text Link to Item
  - Yang, Chi-Fu Jeffrey, Frances McSherry, Nicholas R. Mayne, Xiaofei Wang, Mark F. Berry, Betty Tong, David H. Harpole, et al. “Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer.” Ann Thorac Surg 105, no. 3 (March 2018): 924–29. https://doi.org/10.1016/j.athoracsur.2017.09.030.
    Full Text Link to Item
  - Yi, John S., Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, et al. “Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7474–82. https://doi.org/10.1158/1078-0432.CCR-17-2005.
    Full Text Link to Item
  - Horn, Leora, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, et al. “Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).” J Clin Oncol 35, no. 35 (December 10, 2017): 3924–33. https://doi.org/10.1200/JCO.2017.74.3062.
    Full Text Link to Item
  - Faries, Mark B., Nicola Mozzillo, Mohammed Kashani-Sabet, John F. Thompson, Mark C. Kelley, Ronald C. DeConti, Jeffrey E. Lee, et al. “Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.” Ann Surg Oncol 24, no. 13 (December 2017): 3991–4000. https://doi.org/10.1245/s10434-017-6072-3.
    Full Text Link to Item
  - Stinchcombe, Thomas E., Ying Zhang, Everett E. Vokes, Joan H. Schiller, Jeffrey D. Bradley, Karen Kelly, Walter J. Curran, et al. “Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.” J Clin Oncol 35, no. 25 (September 1, 2017): 2885–92. https://doi.org/10.1200/JCO.2016.71.4758.
    Full Text Link to Item
  - Tandberg, Daniel J., Chris R. Kelsey, Thomas A. D’Amico, Jeffrey Crawford, Junzo P. Chino, Betty C. Tong, Neal E. Ready, and Ato Wright. “Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall.” Clin Lung Cancer 18, no. 4 (July 2017): e259–65. https://doi.org/10.1016/j.cllc.2016.11.008.
    Full Text Link to Item
  - Carbone, David P., Martin Reck, Luis Paz-Ares, Benjamin Creelan, Leora Horn, Martin Steins, Enriqueta Felip, et al. “First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.” N Engl J Med 376, no. 25 (June 22, 2017): 2415–26. https://doi.org/10.1056/NEJMoa1613493.
    Full Text Link to Item
  - Zhou, Fei, Yanru Wang, Hongliang Liu, Neal Ready, Younghun Han, Rayjean J. Hung, Yonathan Brhane, et al. “Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk-A re-analysis of eight GWASs.” Mol Carcinog 56, no. 4 (April 2017): 1227–38. https://doi.org/10.1002/mc.22585.
    Full Text Link to Item
  - Kelley, Michael J., Gautam Jha, Debra Shoemaker, James E. Herndon, Lin Gu, William T. Barry, Jeffrey Crawford, and Neal Ready. “Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.” Cancer Invest 35, no. 1 (January 2, 2017): 32–35. https://doi.org/10.1080/07357907.2016.1253710.
    Full Text Link to Item
  - Hellmann, Matthew D., Naiyer A. Rizvi, Jonathan W. Goldman, Scott N. Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal E. Ready, et al. “Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.” Lancet Oncol 18, no. 1 (January 2017): 31–41. https://doi.org/10.1016/S1470-2045(16)30624-6.
    Full Text Link to Item
  - Rudin, Charles M., M Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, et al. “Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.” Lancet Oncol 18, no. 1 (January 2017): 42–51. https://doi.org/10.1016/S1470-2045(16)30565-4.
    Full Text Link to Item
  - Ryser, Marc D., Walter T. Lee, Neal E. Ready, Kevin Z. Leder, and Jasmine Foo. “Quantifying the Dynamics of Field Cancerization in Tobacco-Related Head and Neck Cancer: A Multiscale Modeling Approach.” Cancer Res 76, no. 24 (December 15, 2016): 7078–88. https://doi.org/10.1158/0008-5472.CAN-16-1054.
    Full Text Link to Item
  - Antonia, Scott J., Scott N. Gettinger, Jonathan Goldman, Julie Brahmer, Hossein Borghaei, Laura Q. Chow, Neal E. Ready, et al. “ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology.” J Thorac Oncol 11, no. 11S (November 2016): S250–51. https://doi.org/10.1016/j.jtho.2016.09.008.
    Full Text Link to Item
  - Gettinger, Scott, Naiyer A. Rizvi, Laura Q. Chow, Hossein Borghaei, Julie Brahmer, Neal Ready, David E. Gerber, et al. “Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.” J Clin Oncol 34, no. 25 (September 1, 2016): 2980–87. https://doi.org/10.1200/JCO.2016.66.9929.
    Full Text Link to Item
  - Boyer, Matthew J., Lin Gu, Xiaofei Wang, Chris R. Kelsey, David S. Yoo, Mark W. Onaitis, Frank R. Dunphy, Jeffrey Crawford, Neal E. Ready, and Joseph K. Salama. “Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.” Lung Cancer 98 (August 2016): 76–78. https://doi.org/10.1016/j.lungcan.2016.05.014.
    Full Text Link to Item
  - Wang, Yanru, Hongliang Liu, Neal E. Ready, Li Su, Yongyue Wei, David C. Christiani, and Qingyi Wei. “Genetic variants in ABCG1 are associated with survival of nonsmall-cell lung cancer patients.” Int J Cancer 138, no. 11 (June 1, 2016): 2592–2601. https://doi.org/10.1002/ijc.29991.
    Full Text Link to Item
  - Kelsey, Chris R., Jared D. Christensen, Junzo P. Chino, Justus Adamson, Neal E. Ready, and Bradford A. Perez. “Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study.” Practical Radiation Oncology 6, no. 2 (March 2016): 96–104. https://doi.org/10.1016/j.prro.2015.10.009.
    Full Text
  - Salama, Joseph K., Lin Gu, Xiaofei Wang, Herbert H. Pang, Jeffrey A. Bogart, Jeffrey Crawford, Steven E. Schild, Everett E. Vokes, and Neal E. Ready. “Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).” J Thorac Oncol 11, no. 3 (March 2016): 361–69. https://doi.org/10.1016/j.jtho.2015.11.001.
    Full Text Link to Item
  - Roe, Matthew T., Derek D. Cyr, Debra Eckart, Phillip J. Schulte, Michael A. Morse, Kimberly L. Blackwell, Neal E. Ready, et al. “Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.” European Heart Journal 37, no. 4 (January 2016): 412–22. https://doi.org/10.1093/eurheartj/ehv611.
    Full Text
  - Clarke, Jeffrey M., Xiaofei Wang, and Neal E. Ready. “Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?” Transl Lung Cancer Res 4, no. 6 (December 2015): 804–8. https://doi.org/10.3978/j.issn.2218-6751.2015.05.03.
    Full Text Link to Item
  - Kelsey, Chris R., Shiva Das, Lin Gu, Frank R. Dunphy, Neal E. Ready, and Lawrence B. Marks. “Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.” International Journal of Radiation Oncology, Biology, Physics 93, no. 5 (December 2015): 997–1004. https://doi.org/10.1016/j.ijrobp.2015.09.007.
    Full Text
  - Borghaei, Hossein, Luis Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal E. Ready, Laura Q. Chow, et al. “Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.” N Engl J Med 373, no. 17 (October 22, 2015): 1627–39. https://doi.org/10.1056/NEJMoa1507643.
    Full Text Link to Item
  - Brahmer, Julie, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried E. E. Eberhardt, Elena Poddubskaya, Scott Antonia, et al. “Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.” N Engl J Med 373, no. 2 (July 9, 2015): 123–35. https://doi.org/10.1056/NEJMoa1504627.
    Full Text Link to Item
  - Ready, Neal E., Herbert H. Pang, Lin Gu, Gregory A. Otterson, Sachdev P. Thomas, Antonius A. Miller, Maria Baggstrom, et al. “Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 15 (May 2015): 1660–65. https://doi.org/10.1200/JCO.2014.57.3105.
    Full Text
  - Pepek, Joseph M., Lawrence B. Marks, Mark F. Berry, Neal E. Ready, Nathan G. Gee, R Edward Coleman, Thomas A. D’Amico, Jeffrey Crawford, and Chris R. Kelsey. “Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.” Practical Radiation Oncology 5, no. 2 (March 2015): 79–84. https://doi.org/10.1016/j.prro.2014.05.002.
    Full Text
  - Boyle, John M., Daniel J. Tandberg, Junzo P. Chino, Thomas A. D’Amico, Neal E. Ready, and Chris R. Kelsey. “Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis.” Cancer 121, no. 4 (February 15, 2015): 598–604. https://doi.org/10.1002/cncr.29095.
    Full Text Link to Item
  - Uronis, Hope E., Jingquan Jia, Johanna C. Bendell, Leigh Howard, Neal A. Ready, Paula H. Lee, Mark D. Starr, et al. “A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.” Cancer Chemotherapy and Pharmacology 75, no. 2 (February 2015): 343–52. https://doi.org/10.1007/s00280-014-2647-x.
    Full Text
  - Stevenson, Marvaretta, Jared Christensen, Debra Shoemaker, Traci Foster, William T. Barry, Betty C. Tong, Momen Wahidi, et al. “Tumor acquisition for biomarker research in lung cancer.” Cancer Investigation 32, no. 6 (July 2014): 291–98. https://doi.org/10.3109/07357907.2014.911880.
    Full Text
  - Denehy, Linda, Whitney E. Hornsby, James E. Herndon, Samantha Thomas, Neal E. Ready, Catherine L. Granger, Lauren Valera, Aarti A. Kenjale, Neil D. Eves, and Lee W. Jones. “Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.” J Thorac Oncol 8, no. 12 (December 2013): 1545–50. https://doi.org/10.1097/JTO.0000000000000032.
    Full Text Link to Item
  - Tandberg, Daniel J., Nathan G. Gee, Junzo P. Chino, Thomas A. D’Amico, Neal E. Ready, R Edward Coleman, and Chris R. Kelsey. “Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?” J Thorac Cardiovasc Surg 146, no. 4 (October 2013): 796–801. https://doi.org/10.1016/j.jtcvs.2013.05.027.
    Full Text Link to Item
  - Washington, Iman, Junzo P. Chino, Lawrence B. Marks, Thomas A. D’Amico, Mark F. Berry, Neal E. Ready, Kristin A. Higgins, David S. Yoo, and Chris R. Kelsey. “Diabetes mellitus: A significant co-morbidity in the setting of lung cancer?” Thorac Cancer 4, no. 2 (May 2013): 123–30. https://doi.org/10.1111/j.1759-7714.2012.00162.x.
    Full Text Link to Item
  - Kalemkerian, Gregory P., Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Qm Chow, Robert J. Downey, Leena Gandhi, et al. “Small cell lung cancer.” J Natl Compr Canc Netw 11, no. 1 (January 1, 2013): 78–98. https://doi.org/10.6004/jnccn.2013.0011.
    Full Text Link to Item
  - Roe, Matthew T., Paul W. Armstrong, Keith A. A. Fox, Harvey D. White, Dorairaj Prabhakaran, Shaun G. Goodman, Jan H. Cornel, et al. “Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.” N Engl J Med 367, no. 14 (October 4, 2012): 1297–1309. https://doi.org/10.1056/NEJMoa1205512.
    Full Text Link to Item
  - Higgins, Kristin A., Junzo P. Chino, Neal Ready, Thomas A. D’Amico, Mark F. Berry, Thomas Sporn, Jessamy Boyd, and Chris R. Kelsey. “Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.” J Thorac Oncol 7, no. 7 (July 2012): 1141–47. https://doi.org/10.1097/JTO.0b013e3182519a42.
    Full Text Link to Item
  - Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.
    Full Text Link to Item
  - Cuneo, K. C., T. M. Zagar, D. M. Brizel, D. S. Yoo, J. K. Hoang, Z. Chang, Z. Wang, et al. “Stereotactic radiotherapy for malignancies involving the trigeminal and facial nerves.” Technol Cancer Res Treat 11, no. 3 (June 2012): 221–28. https://doi.org/10.7785/tcrt.2012.500290.
    Full Text Link to Item
  - Higgins, Kristin A., Junzo P. Chino, Mark Berry, Neal Ready, Jessamy Boyd, David S. Yoo, and Chris R. Kelsey. “Local failure in resected N1 lung cancer: implications for adjuvant therapy.” Int J Radiat Oncol Biol Phys 83, no. 2 (June 1, 2012): 727–33. https://doi.org/10.1016/j.ijrobp.2011.07.018.
    Full Text Link to Item
  - Lee, Walter T., David S. Yoo, Liana Puscas, David Witsell, Seth M. Cohen, Samuel R. Fisher, Richard Scher, et al. “Treatment-induced changes in vocal cord mobility and subsequent local recurrence after organ preservation therapy for laryngeal carcinoma.” Head Neck 34, no. 6 (June 2012): 792–96. https://doi.org/10.1002/hed.21813.
    Full Text Link to Item
  - Yoo, David S., John P. Kirkpatrick, Oana Craciunescu, Gloria Broadwater, Bercedis L. Peterson, Madeline D. Carroll, Robert Clough, et al. “Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer.” Clin Cancer Res 18, no. 5 (March 1, 2012): 1404–14. https://doi.org/10.1158/1078-0432.CCR-11-1982.
    Full Text Link to Item
  - Ready, Neal E., Ritesh Rathore, Tirrell T. Johnson, Ahmed Nadeem, Prakash Chougule, Charles Ruhl, Kathy Radie-Keane, et al. “Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck.” Am J Clin Oncol 35, no. 1 (February 2012): 6–12. https://doi.org/10.1097/COC.0b013e3182019ee3.
    Full Text Link to Item
  - Ready, Neal E., Arkadiusz Z. Dudek, Herbert H. Pang, Lydia D. Hodgson, Stephen L. Graziano, Mark R. Green, and Everett E. Vokes. “Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.” J Clin Oncol 29, no. 33 (November 20, 2011): 4436–41. https://doi.org/10.1200/JCO.2011.35.6923.
    Full Text Link to Item
  - Higgins, Kristin A., Junzo P. Chino, Neal Ready, Mark W. Onaitis, Mark F. Berry, Thomas A. D’Amico, and Chris R. Kelsey. “Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer.” J Thorac Cardiovasc Surg 142, no. 5 (November 2011): 1175–79. https://doi.org/10.1016/j.jtcvs.2011.07.059.
    Full Text Link to Item
  - Wanebo, Harold J., Ritesh Rathore, Prakash Chougule, Michael R. DiSiena, R James Koness, Robert G. McRae, Peter T. Nigri, Kathy Radie-Keane, and Neal Ready. “Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies.” Ann Surg Oncol 18, no. 12 (November 2011): 3479–85. https://doi.org/10.1245/s10434-011-1697-0.
    Full Text Link to Item
  - Kalemkerian, Gregory P., Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, et al. “Small cell lung cancer.” J Natl Compr Canc Netw 9, no. 10 (October 2011): 1086–1113. https://doi.org/10.6004/jnccn.2011.0092.
    Full Text Link to Item
  - Ahmed, Shair, Ariel E. Birnbaum, Howard P. Safran, Thomas A. Dipetrillo, Bassam I. Aswad, Neal E. Ready, and Thomas Ng. “Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.” J Thorac Oncol 6, no. 8 (August 2011): 1432–34. https://doi.org/10.1097/JTO.0b013e3182209043.
    Full Text Link to Item
  - Pepek, Joseph M., Junzo P. Chino, Lawrence B. Marks, Thomas A. D’amico, David S. Yoo, Mark W. Onaitis, Neal E. Ready, Jessica L. Hubbs, Jessamy Boyd, and Chris R. Kelsey. “How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems.” J Thorac Oncol 6, no. 4 (April 2011): 757–61. https://doi.org/10.1097/JTO.0b013e31821038c0.
    Full Text Link to Item
  - Ready, Neal, Nina A. Karaseva, Sergey V. Orlov, Alexander V. Luft, Olexandr Popovych, Jon T. Holmlund, Brian A. Wood, and Lance Leopold. “Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.” J Thorac Oncol 6, no. 4 (April 2011): 781–85. https://doi.org/10.1097/JTO.0b013e31820a0ea6.
    Full Text Link to Item
  - Rathore, Ritesh, Ariel Birnbaum, Bharti Rathore, Thomas DiPetrillo, Teresa Kennedy, and Neal Ready. “Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93).” Cancer Chemother Pharmacol 66, no. 6 (November 2010): 1013–17. https://doi.org/10.1007/s00280-010-1251-y.
    Full Text Link to Item
  - Ready, Neal, Pasi A. Jänne, Jeffrey Bogart, Thomas Dipetrillo, Jennifer Garst, Stephen Graziano, Lin Gu, et al. “Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.” J Thorac Oncol 5, no. 9 (September 2010): 1382–90. https://doi.org/10.1097/JTO.0b013e3181eba657.
    Full Text Link to Item
  - Birnbaum, Ariel, Thomas Dipetrillo, Ritesh Rathore, Elliott Anderson, Harry Wanebo, Yacoub Puthwala, Donald Joyce, et al. “Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.” Am J Clin Oncol 33, no. 2 (April 2010): 144–47. https://doi.org/10.1097/COC.0b013e3181979093.
    Full Text Link to Item
  - Stevenson, Marvaretta, William Mostertz, Chaitanya Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, et al. “Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.” Clin Cancer Res 15, no. 24 (December 15, 2009): 7553–61. https://doi.org/10.1158/1078-0432.CCR-09-1939.
    Full Text Link to Item
  - Higgins, Kristin, Junzo P. Chino, Lawrence B. Marks, Neal Ready, Thomas A. D’Amico, Robert W. Clough, and Chris R. Kelsey. “Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.” Int J Radiat Oncol Biol Phys 75, no. 5 (December 1, 2009): 1462–67. https://doi.org/10.1016/j.ijrobp.2009.01.069.
    Full Text Link to Item
  - Kelsey, Chris R., Lawrence B. Marks, Donna Hollis, Jessica L. Hubbs, Neal E. Ready, Thomas A. D’Amico, and Jessamy A. Boyd. “Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients.” Cancer 115, no. 22 (November 15, 2009): 5218–27. https://doi.org/10.1002/cncr.24625.
    Full Text Link to Item
  - Hirsh, Rebecca, Dilip Giri, Rogers Griffith, Richard Stone, and Neal Ready. “Langerhans cell histiocytosis following acute leukemia in an adult.” Am J Hematol 84, no. 10 (October 2009): 693–94. https://doi.org/10.1002/ajh.21490.
    Full Text Link to Item
  - Zhu, Andrew X., Neal Ready, Jeffrey W. Clark, Howard Safran, Antonino Amato, Nadia Salem, Silvia Pace, et al. “Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.” Clin Cancer Res 15, no. 1 (January 1, 2009): 374–81. https://doi.org/10.1158/1078-0432.CCR-08-1024.
    Full Text Link to Item
  - Chougule, Prakash B., Muhammad S. Akhtar, Ritesh Rathore, James Koness, Robert McRae, Peter Nigri, Kathie Radie-Keane, Teresa Kennedy, Harold J. Wanebo, and Neal Ready. “Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53).” Head Neck 30, no. 3 (March 2008): 289–96. https://doi.org/10.1002/hed.20700.
    Full Text Link to Item
  - Kalemkerian, Gregory P., Wallace Akerley, Robert J. Downey, David S. Ettinger, Frank Fossella, John C. Grecula, Thierry Jahan, et al. “Small cell lung cancer.” J Natl Compr Canc Netw 6, no. 3 (March 2008): 294–314.
    Link to Item
  - Grieco, C Alexander, Caroline J. Simon, William W. Mayo-Smith, Thomas A. Dipetrillo, Neal E. Ready, and Damian E. Dupuy. “Image-guided percutaneous thermal ablation for the palliative treatment of chest wall masses.” Am J Clin Oncol 30, no. 4 (August 2007): 361–67. https://doi.org/10.1097/COC.0b013e318033e76a.
    Full Text Link to Item
  - Shah, Chirag, Neal Ready, Michel Perry, Jeffrey Kirshner, Ajeet Gajra, Nancy Neuman, and Stephen Garziano. “A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.” Lung Cancer 57, no. 1 (July 2007): 84–88. https://doi.org/10.1016/j.lungcan.2007.02.014.
    Full Text Link to Item
  - Ready, Neal E., Alan Lipton, Yali Zhu, Paul Statkevich, Emily Frank, Dolores Curtis, and Ronald M. Bukowski. “Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.” Clin Cancer Res 13, no. 2 Pt 1 (January 15, 2007): 576–83. https://doi.org/10.1158/1078-0432.CCR-06-1262.
    Full Text Link to Item
  - Akerley, Wallace, Howard Safran, Ken Zaner, Neal Ready, Tony Mega, and Teresa Kennedy. “Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.” Cancer 107, no. 5 (September 1, 2006): 1050–54. https://doi.org/10.1002/cncr.22095.
    Full Text Link to Item
  - Grieco, C Alexander, Caroline J. Simon, William W. Mayo-Smith, Thomas A. DiPetrillo, Neal E. Ready, and Damian E. Dupuy. “Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer.” J Vasc Interv Radiol 17, no. 7 (July 2006): 1117–24. https://doi.org/10.1097/01.RVI.0000228373.58498.6E.
    Full Text Link to Item
  - Dupuy, Damian E., Thomas DiPetrillo, Sachin Gandhi, Neal Ready, Thomas Ng, Walter Donat, and William W. Mayo-Smith. “Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer.” Chest 129, no. 3 (March 2006): 738–45. https://doi.org/10.1378/chest.129.3.738.
    Full Text Link to Item
  - Ready, Neal, Frederick Aronson, Harold Wanebo, and Theresa Kennedy. “A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.” Am J Clin Oncol 28, no. 5 (October 2005): 479–84. https://doi.org/10.1097/01.coc.0000164006.72694.1b.
    Full Text Link to Item
  - Ready, Neal. “Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.” Seminars in Oncology 32, no. 2 Suppl 3 (April 2005): S35–41. https://doi.org/10.1053/j.seminoncol.2005.03.008.
    Full Text
  - Birnbaum, Ariel, and Neal Ready. “Gefitinib therapy for non-small cell lung cancer.” Curr Treat Options Oncol 6, no. 1 (January 2005): 75–81. https://doi.org/10.1007/s11864-005-0015-0.
    Full Text Link to Item
  - Cox, J. D., T. Le Chevalier, R. Arriagada, H. Choy, W. J. Curran, M. Fukuoka, P. Harper, et al. “Management of unresectable non-small cell carcinoma of the lung (NSCLC).” Lung Cancer (Amsterdam, Netherlands) 42 Suppl 1 (December 2003): S15–16. https://doi.org/10.1016/s0169-5002(03)00298-8.
    Full Text
  - Postmus, Pieter E., Pierre Rocmans, Hisao Asamura, David Ball, José Belderbos, Matteo Cappello, Jacek Jassem, et al. “Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer.” Lung Cancer (Amsterdam, Netherlands) 42 Suppl 1 (December 2003): S3–6. https://doi.org/10.1016/s0169-5002(03)00296-4.
    Full Text
  - Ready, Neal E., and Everett E. Vokes. “Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer.” Lung Cancer (Amsterdam, Netherlands) 42 Suppl 1 (December 2003): S65–69. https://doi.org/10.1016/s0169-5002(03)00306-4.
    Full Text
  - Ready, Neal, and Martin A. Weinstock. “Adjuvant high-dose interferon therapy for high-risk melanoma.” Arch Dermatol 139, no. 12 (December 2003): 1635–37. https://doi.org/10.1001/archderm.139.12.1635.
    Full Text Link to Item
  - Ready, N., and M. A. Weinstock. “Elective lymph node dissection for melanoma laid to rest yet again.” Archives of Dermatology 139, no. 9 (September 1, 2003): 1203–4. https://doi.org/10.1001/archderm.139.9.1203.
    Full Text
  - Akerley, Wallace, Ritesh Rathore, Neil Ready, Louis Leone, William Sikov, Howard Safran, and Teresa Kennedy. “A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma.” Cancer 95, no. 9 (November 1, 2002): 2000–2005. https://doi.org/10.1002/cncr.10902.
    Full Text Link to Item
  - Moore, Todd, and Neal Ready. “Update in non-small cell lung cancer.” Med Health R I 85, no. 1 (January 2002): 7–9.
    Link to Item
  - Wanebo, H., P. Chougule, N. Ready, H. Safran, W. Ackerley, R. J. Koness, R. McRae, et al. “Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV).” Ann Surg Oncol 8, no. 8 (September 2001): 644–50. https://doi.org/10.1007/s10434-001-0644-x.
    Full Text Link to Item
  - Chougule, P. B., M. S. Akhtar, W. Akerley, N. Ready, H. Safran, R. McRae, P. Nigri, et al. “Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.” Semin Radiat Oncol 9, no. 2 Suppl 1 (April 1999): 58–63.
    Link to Item
  - Wanebo, H. J., P. Chougule, N. Ready, R. J. Koness, W. Akerley, R. McRae, P. Nigri, L. Leone, B. Webber, and H. Safran. “Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV).” Semin Radiat Oncol 9, no. 2 Suppl 1 (April 1999): 77–84.
    Link to Item
  - Kluger, N. J., F. J. Cummings, N. E. Ready, J. D. Sweeney, and A. B. Weitberg. “Post transfusion non-cardiogenic pulmonary edema in a patient with chemotherapy-related hemolytic uremic syndrome.” Med Health R I 81, no. 7 (July 1998): 235–36.
    Link to Item
  - Chougule, P., H. Wanebo, W. Akerley, R. McRae, P. Nigri, L. Leone, H. Safran, et al. “Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results.” Semin Oncol 24, no. 6 Suppl 19 (December 1997): S19-57-S19-61.
    Link to Item
  - Wanebo, H. J., P. Chougule, W. L. Akerley, R. J. Koness, R. McRae, P. Nigri, L. Leone, et al. “Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer.” Am J Surg 174, no. 5 (November 1997): 518–22. https://doi.org/10.1016/s0002-9610(97)00167-0.
    Full Text Link to Item
  - Celi, A., G. Pellegrini, R. Lorenzet, A. De Blasi, N. Ready, B. C. Furie, and B. Furie. “P-selectin induces the expression of tissue factor on monocytes.” Proc Natl Acad Sci U S A 91, no. 19 (September 13, 1994): 8767–71. https://doi.org/10.1073/pnas.91.19.8767.
    Full Text Link to Item
  - Ready, N., N. J. Freeman, and A. Carvalho. “Treatment choices in chronic myelogenous leukemia.” Hosp Pract (Off Ed) 27, no. 9A (September 30, 1992): 95–101.
    Link to Item
  - Ready, N. E. “Development of fast singing muscles in a katydid.” J Exp Zool 238, no. 1 (April 1986): 43–54. https://doi.org/10.1002/jez.1402380106.
    Full Text Link to Item
  - Mizisin, A. P., and N. E. Ready. “Growth and development of flight muscle in the locust (Schistocerca nitens, Thünberg).” Journal of Experimental Zoology 237, no. 1 (January 1, 1986): 45–55. https://doi.org/10.1002/jez.1402370108.
    Full Text
  - "Structural and functional development of cricket wing muscles." Journal of Experimental Zoology 233, no. 1 (January 1, 1985): 3550-null.
  - Ready, N. E., and R. E. Najm. “Structural and functional development of cricket ring muscles.” J Exp Zool 233, no. 1 (January 1985): 35–50. https://doi.org/10.1002/jez.1402330107.
    Full Text Link to Item
  - Oglesby, L. C., C. P. Mangum, A. E. Heacox, and N. E. Ready. “Salt and water balance in the polychaete Nereis virens.” Comparative Biochemistry and Physiology Part A: Physiology 73, no. 1 (January 1, 1982): 15–19. https://doi.org/10.1016/0300-9629(82)90085-8.
    Full Text
  - Ready, N. E., and R. K. Josephson. “Flight muscle development in a hemimetabolous insect.” Journal of Experimental Zoology 220, no. 1 (January 1, 1982): 49–56. https://doi.org/10.1002/jez.1402200107.
    Full Text
- Other Articles
  - Stevenson, Marvaretta, William Mostertz, Chaitanya R. Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, et al. “Retraction: characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.” Clin Cancer Res, March 15, 2012. https://doi.org/10.1158/1078-0432.CCR-12-0337.
    Full Text Link to Item
- Conference Papers
  - Jacobs, C. D., J. Gao, X. Wang, N. E. Ready, J. Clarke, B. Tong, C. R. Kelsey, G. Suneja, and J. A. Torok. “Definitive Radiotherapy for Inoperable Stage IIB Non-Small Cell Lung Cancer: Patterns of Care and Comparative Effectiveness Analyses Using the National Cancer Database.” In International Journal of Radiation Oncology*Biology*Physics, 104:243–243. Elsevier BV, 2019. https://doi.org/10.1016/j.ijrobp.2019.01.042.
    Full Text
  - Tan, Irena, Tom Stinchcombe, Neal E. Ready, Michael B. Datto, Rebecca J. Nagy, Lin Gu, and Jeffrey Melson Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study.” In Journal of Clinical Oncology, 36:e21222–e21222. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e21222.
    Full Text
  - Siu, L., C. Even, R. Mesia, A. Daste, J. Krauss, N. F. Saba, L. Nabell, et al. “A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR.” In International Journal of Radiation Oncology Biology Physics, 100:1307–1307. ELSEVIER SCIENCE INC, 2018.
    Link to Item
  - Goldman, Jonathan Wade, Scott Joseph Antonia, Scott N. Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal E. Ready, David E. Gerber, et al. “Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.” In Journal of Clinical Oncology, 35:9093–9093. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.9093.
    Full Text
  - Liu, Stephen V., D Ross Camidge, Scott N. Gettinger, Giuseppe Giaccone, Rebecca Suk Heist, F Stephen Hodi, Neal E. Ready, et al. “Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.” In Journal of Clinical Oncology, 35:9092–9092. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.9092.
    Full Text
  - Antonia, Scott J., Scott N. Gettinger, Jonathan Goldman, Julie Brahmer, Hossein Borghaei, Laura Q. Chow, Neal E. Ready, et al. “CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC.” In Journal of Thoracic Oncology, 11:S250–51. ELSEVIER SCIENCE INC, 2016.
    Link to Item
  - Barlesi, F., M. Steins, L. Horn, N. Ready, E. Felip, H. Borghaei, D. R. Spigel, et al. “Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update.” In Annals of Oncology, 27:vi420, 2016. https://doi.org/10.1093/annonc/mdw383.15.
    Full Text
  - Gettinger, S. N., M. D. Hellmann, F. A. Shepherd, S. J. Antonia, J. Brahmer, L. Q. Chow, J. Goldman, et al. “3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses.” In European Journal of Cancer, 51:S632–S632. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31737-3.
    Full Text
  - Horn, L., J. Brahmer, M. Reck, H. Borghaei, D. R. Spigel, M. Steins, N. E. Ready, et al. “3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs).” In European Journal of Cancer, 51:S599–S599. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31655-0.
    Full Text
  - Pietanza, M. C., D. Spigel, T. M. Bauer, N. E. Ready, B. S. Glisson, D. Morgensztern, F. Robert, et al. “7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC).” In European Journal of Cancer, 51:S712–S712. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31931-1.
    Full Text
  - Antonia, Scott J., Scott Gettinger, Laura Q. Chow, Rosalyn Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Allen C. Chen, Neal E. Ready, and Naiyer A. Rizvi. “NIVOLUMAB AND IPILIMUMAB IN FIRST-LINE NON-SMALL-CELL LUNG CARCINOMA (NSCLC): INTERIM PHASE I RESULTS.” In Asia Pacific Journal of Clinical Oncology, 10:155–155. WILEY-BLACKWELL, 2014.
    Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

External Relationships

Selected Publications

Academic Articles

Other Articles

Conference Papers